Angiotensin II Stimulates Matrix Metalloproteinase Secretion in Human Vascular Smooth Muscle Cells via Nuclear Factor-κB and Activator Protein 1 in a Redox-Sensitive Manner
暂无分享,去创建一个
H. Katus | S. Gehrke | Joachim W. Schmidt | R. Kranzhöfer | M. Browatzki | Dina Larsen | C. A. Pfeiffer | A. Kranzhöfer
[1] P. López-Jaramillo,et al. Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-α , 2004 .
[2] R. Muraro,et al. Blockade of the Angiotensin II Type 1 Receptor Stabilizes Atherosclerotic Plaques in Humans by Inhibiting Prostaglandin E2–Dependent Matrix Metalloproteinase Activity , 2004, Circulation.
[3] R. Visse,et al. This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .
[4] Norman Honbo,et al. A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. , 2003, The Biochemical journal.
[5] F. Pieruzzi,et al. ANG II increases TIMP-1 expression in rat aortic smooth muscle cells in vivo. , 2003, American journal of physiology. Heart and circulatory physiology.
[6] B. Greenberg,et al. Molecular Medicine Tumor Necrosis Factor-�–Induced AT 1 Receptor Upregulation Enhances Angiotensin II–Mediated Cardiac Fibroblast Responses That Favor Fibrosis , 2022 .
[7] C. Ferrario,et al. Mechanisms linking angiotensin II and atherogenesis , 2002, Current opinion in lipidology.
[8] J. Mehta,et al. Modulation of Matrix Metalloproteinase-1, Its Tissue Inhibitor, and Nuclear Factor-&kgr;B by Losartan in Hypercholesterolemic Rabbits , 2002, Journal of cardiovascular pharmacology.
[9] M. Böhm,et al. Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts. , 2002, Journal of molecular and cellular cardiology.
[10] G. Karakiulakis,et al. Losartan Inhibits the Angiotensin II–Induced Modifications on Fibrinolysis and Matrix Deposition by Primary Human Vascular Smooth Muscle Cells , 2001, Journal of cardiovascular pharmacology.
[11] J. Rutter,et al. Synergistic induction of matrix metalloproteinase 1 by interleukin-1alpha and oncostatin M in human chondrocytes involves signal transducer and activator of transcription and activator protein 1 transcription factors via a novel mechanism. , 2001, Arthritis and rheumatism.
[12] L. Oberley,et al. H2O2-induced O⨪2Production by a Non-phagocytic NAD(P)H Oxidase Causes Oxidant Injury* , 2001, The Journal of Biological Chemistry.
[13] F. Spinale,et al. Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation. , 2001, American journal of physiology. Heart and circulatory physiology.
[14] A. Newby,et al. Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. , 2001, Cardiovascular research.
[15] Kukin Ml. The Heart Outcomes Prevention Evaluation Study. , 2001, Current cardiology reports.
[16] M. Nishino,et al. Increased Angiotensin-Converting Enzyme Activity in Coronary Artery Specimens From Patients With Acute Coronary Syndrome , 2001, Circulation.
[17] R. Brandes,et al. The terminal complement complex C5b‐9 stimulates interleukin‐6 production in human smooth‐muscle cells through activation of transcription factors NF‐κB and AP‐1 , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[18] K. Schmidt-Ott,et al. The multiple actions of angiotensin II in atherosclerosis , 2000, Regulatory Peptides.
[19] T. Bocan,et al. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition. , 2000, Cardiovascular research.
[20] W. Kübler,et al. Endothelin-1 induces interleukin-6 release via acctivation of the transcription factor NF-κB in human vascular smooth muscle cells , 2000, Basic Research in Cardiology.
[21] W Kübler,et al. Differential activation of mitogen-activated protein kinases in smooth muscle cells by angiotensin II: involvement of p22phox and reactive oxygen species. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[22] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[23] S. Yusuf,et al. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. , 2000 .
[24] K. Ohnaka,et al. Induction of cyclooxygenase-2 by angiotensin II in cultured rat vascular smooth muscle cells. , 2000, Hypertension.
[25] Ashutosh Kumar Singh,et al. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. , 1999, Diabetes.
[26] J. Pickering,et al. Angiotensin II stimulates collagen synthesis in human vascular smooth muscle cells. Involvement of the AT(1) receptor, transforming growth factor-beta, and tyrosine phosphorylation. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[27] P. Libby,et al. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[28] P. Libby,et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. , 1999, Circulation.
[29] W. Kübler,et al. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. , 1999, Biochemical and biophysical research communications.
[30] M. Runge,et al. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. , 1999, Circulation research.
[31] L. Arroyo,et al. Mechanisms of plaque rupture: mechanical and biologic interactions. , 1999, Cardiovascular research.
[32] R. Alexander,et al. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. , 1998, Circulation research.
[33] D. Kass,et al. Synergistic exacerbation of diastolic stiffness from short-term tachycardia-induced cardiodepression and angiotensin II. , 1998, Circulation research.
[34] D. Harrison,et al. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. , 1996, The Journal of clinical investigation.
[35] K. Weber,et al. Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. , 1995, The American journal of cardiology.
[36] P. Libby. Molecular bases of the acute coronary syndromes. , 1995, Circulation.
[37] P. Libby,et al. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[38] S. Orrenius,et al. Different prooxidant levels stimulate growth, trigger apoptosis, or produce necrosis of insulin-secreting RINm5F cells. The role of intracellular polyamines. , 1994, The Journal of biological chemistry.
[39] P. Libby,et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.
[40] G. Lamas,et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. , 1994, Circulation.
[41] P. Libby,et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. , 1994, Circulation research.
[42] T. Resink,et al. Activation of human peripheral monocytes by angiotensin II , 1994, FEBS letters.
[43] R W Alexander,et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. , 1994, Circulation research.
[44] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[45] A. Gown,et al. HHF35, a muscle actin-specific monoclonal antibody. II. Reactivity in normal, reactive, and neoplastic human tissues. , 1987, The American journal of pathology.
[46] P. Libby,et al. Culture of quiescent arterial smooth muscle cells in a defined serum‐free medium , 1983, Journal of cellular physiology.